نبذة مختصرة : Human brain tumors are a group of tumors that primarily originate from the central nervous system. These tumors vary in their etiology, histology, biology, prognosis and treatment. The overall incident rate of brain tumors are reported to be lower compared to other human tumor types. However, it results in a disproportionately high mortality rate due to cancers. The human retinoblastoma gene (RBI) is the first human tumor suppressor (TS) gene to be identified and it is one of the most widely studied genes in a variety of human cancers. Data from these studies showed that it is one of the most important cell cycle regulatory genes. Inactivation of RBI gene has been reported in various human tumors including brain tumors. Data from the Western population indicates that the TS function of this gene is lost due to deletions, mutations or absence of its protein product in a considerable number of human brain tumor cases. To the contrary, data from the brain tumor tissues of Indian population indicates that the inactivation of RBI gene pathway could occur though a different mechanism. This could abo explain the rarity of retinoblastomas, one of the childhood tumors, in Indian population. In this review we have discussed the possible role RBI gene in the development of human brain tumors.doi:10.5214/ans.0972.7531.2007.140304
Rights: The corresponding author should agree, by the act of submission, that the copyright of the manuscript, was in fact transferred to the journal and would be done so without any renumeration from the Journal, such transfer being irrevocable after publication. Authors hold the right to withdraw any manuscript from consideration for publication for any reason until the issue was copyset for publication, after which the manuscripts would be retracted. On behalf of all authors the submitting author should either be the corresponding author or if not, the corresponding author should assert by submission of any and all manuscripts for review that the manuscript is not under consideration elsewhere. That all individuals who participated in the study in a material manner are listed as authors, or if not, why. That all authors have reviewed and agree with the content, presentation, organization, data and interpretation of the data or the manuscript as well as their position within the authorship list, that no individual who either holds or claims any authorship right has been excluded and if not, explain, that the facts of the paper are true and honest and that all experiments that require institutional or governmental approval have been submitted, evaluated and awarded required approvals including but not limited to human experimentation and clinical trials, animal use, use of toxic chemicals and radioactive elements, regulators pertaining to any and all aspects of ICMR-DBT guidelines of stem cell research if applicable, or any other regulation pertinent to the study. On behalf of all authors, the corresponding author agrees to be listed as such, and all other authors consent to this listing. The listed corresponding author on behalf of all authors by submission of the paper for review or publication testifies that he or she is reasonably certain that the data presented are accurate, has no reason to question the validity of any fact, statement or experimental result presented in the paper, has directly participated in all aspects of the study has not copied the work or any aspect of it from another source, has not reviewed any paper that presents substantially identical results and has in fact not accepted that paper for publication or is aware that the paper is no longer being evaluated for publication unless that paper is referred to by reference of footnote in the submitted manuscript, that any and all future allegations of scientific misconduct or fraud that arise from either the submission or publication of the paper shall be relayed to the editor in chief in timely manner and that the proceedings of any investigation will be communicated as they evolve, that the journal reserves the right to publish such information if that information is in fact in the public domain and to comment upon it as the findings if invalid relate to the science communicated by the Journal.
Processing Request
No Comments.